2025乳房醫學線上研討會，今年度共3場會議，此場為最後一場!在乳e學院線上進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!

活動日期：114年08月16日(週六)12:30-17:20(含課前及課後測驗時間)   課程直播過程如有異常請及時洽詢台灣乳房醫學會(02-2523-9118；bcst@ms46.hinet.net)
活動地點：線上直播。
主辦單位：台灣乳房醫學會
指導單位：衛生福利部國民健康署
課程表：課程總表；第四場課表
乳e學院介面操作手冊：請點此下載操作手冊

本堂課程認證學分申請中，如以下：
1.台灣乳房醫學會：5分
2.台灣外科醫學會：1積點
3.台灣醫學會：4.2分
4台灣護理學會：3.6分
5.台灣專科護理師學會：專科護理師2分
6.中華民國醫事放射學會：4.2分
7.中華民國放射線醫學會：1積點
8.中華民國癌症醫學會：腫瘤內科A類3學分、腫瘤外科A類3學分
9.中華民國醫用超音波學會：5分
10.公務人員時數：4小時
11.國民健康署疑異(疑陽)時數：4小時 
12.國民健康署乳篩時數：2小時 (本系列課程共同認列乳篩時數，當年度累積上限為3小時，且共計於年底一併上傳時數，詳細資訊請洽相關單位)

• 備註：
  本乳e學院平台系統中「積分登錄期間」係指學員於該時段完成課程，得獲取時數積分認證資格；「課程開放閱讀期間」係指包含報名、預習、複習等課程開放時段，惟複習等僅作為個人學習，並不包含測驗以及積分認證。
  若欲取得本堂課時數積分，請務必於「積分登錄期間」註記時間內參與並完成課程。

In hormone receptor-positive (HR+) breast cancer, the tumor immune microenvironment (TIM) is uniquely shaped by estrogen signaling, which not only suppresses immune activity but also fosters a microenvironment conducive to late recurrence. This makes late recurrence a critical issue that must not be underestimated in these patients. 

Estrogen promotes immunosuppressive mechanisms, such as polarizing macrophages toward the M2 subtype and enhancing Tregs and myeloid-derived suppressor cells (MDSCs). Conversely, CDK4/6 inhibitors and endocrine therapies offer a dual benefit: they block estrogen signaling while also reshaping the TIM. CDK4/6 inhibitors, in particular, have shown promise in triggering anti-tumor immunity and reducing recurrence risk. Excitingly, ongoing research is exploring how different CDK4/6 inhibitors uniquely modulate the TIM, potentially paving the way for more precise and effective treatment strategies in HR+ breast cancer.

Sacituzumab Govitecan (SG; Trodelvy) is a targeted therapy designed for adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who have received hormone therapy and at least two additional treatments for metastatic disease. It is an antibody-drug conjugate that binds to the Trop-2 antigen, delivering a potent chemotherapy directly to cancer cells6. Clinical trials have demonstrated that SG significantly improves progression-free survival and overall survival compared to traditional chemotherapy in this patient population. This therapy offers a new treatment option for patients with HR+/HER2- MBC, who historically have had limited treatment choices and poor survival outcomes. SG's mechanism of action and clinical efficacy make it a valuable addition to the treatment landscape for this challenging form of breast cancer.

誠摯歡迎各位學員於11月19日(二)18:40登入乳e學院並”加入我的課程+”，收看聆聽講師們分享2024 ESMO治療最新趨勢

2025乳房醫學線上研討會，今年度共3場會議，將於6/27, 7/25, 08/29，在乳e學院線上進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!